Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 29:15:1331641.
doi: 10.3389/fimmu.2024.1331641. eCollection 2024.

The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy

Affiliations
Review

The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy

Dongming Li et al. Front Immunol. .

Abstract

Cancer, a disease that modern medicine has not fully understood and conquered, with its high incidence and mortality, deprives countless patients of health and even life. According to global cancer statistics, there were an estimated 19.3 million new cancer cases and nearly 10 million cancer deaths in 2020, with the age-standardized incidence and mortality rates of 201.0 and 100.7 per 100,000, respectively. Although remarkable advancements have been made in therapeutic strategies recently, the overall prognosis of cancer patients remains not optimistic. Consequently, there are still many severe challenges to be faced and difficult problems to be solved in cancer therapy today. Epigallocatechin gallate (EGCG), a natural polyphenol extracted from tea leaves, has received much attention for its antitumor effects. Accumulating investigations have confirmed that EGCG can inhibit tumorigenesis and progression by triggering apoptosis, suppressing proliferation, invasion, and migration, altering tumor epigenetic modification, and overcoming chemotherapy resistance. Nevertheless, its regulatory roles and biomolecular mechanisms in the immune microenvironment, metabolic microenvironment, and immunotherapy remain obscure. In this article, we summarized the most recent updates about the effects of EGCG on tumor microenvironment (TME), metabolic reprogramming, and anti-cancer immunotherapy. The results demonstrated EGCG can promote the anti-cancer immune response of cytotoxic lymphocytes and dendritic cells (DCs), attenuate the immunosuppression of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), and inhibit the tumor-promoting functions of tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), and various stromal cells including cancer-associated fibroblasts (CAFs), endothelial cells (ECs), stellate cells, and mesenchymal stem/stromal cells (MSCs). Additionally, EGCG can suppress multiple metabolic reprogramming pathways, including glucose uptake, aerobic glycolysis, glutamine metabolism, fatty acid anabolism, and nucleotide synthesis. Finally, EGCG, as an immunomodulator and immune checkpoint blockade, can enhance immunotherapeutic efficacy and may be a promising candidate for antitumor immunotherapy. In conclusion, EGCG plays versatile regulatory roles in TME and metabolic reprogramming, which provides novel insights and combined therapeutic strategies for cancer immunotherapy.

Keywords: antitumor immunity; epigallocatechin gallate; immunotherapy; metabolic reprogramming; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Main effects and molecular mechanisms of EGCG on immune cells, including T lymphocytes, NK cells, DCs, MDSCs, Tregs, TAMs, and TANs in tumor microenvironment. EGCG enhances the infiltration and antitumor immune response of cytotoxic lymphocytes, promotes the maturation and tumor antigen loading of DCs, attenuates the immunosuppressive effect of MDSCs and Tregs, and blocks the regulation of TAMs and TANs on tumor promotion, involving various biomolecular targets, such as STAT, NF-κB, TGF-β, TLR4, PI3K/Akt, PD-L1, IDO, and their relevant signaling pathways. The figure was drawn using Figdraw.
Figure 2
Figure 2
Main effects and molecular mechanisms of EGCG on tumor stromal cells, including CAFs, ECs, stellate cells, and MSCs in tumor microenvironment. EGCG inhibits tumor stromal cell activation, adhesion, proliferation, migration, inflammatory cytokine and chemokine secretion, actin polymerization, ECM remodeling, and angiogenesis. Main molecular mechanisms may be attributed to the inhibitory effect of EGCG on Rho/ROCK, ECM/integrin, RTKs/PI3K/Akt/mTOR, TGF-β/Samd, MAPK/ERK, JAK/STAT3, NF-κB, 67LR/TLR4, and HIF-1α signaling pathways. The figure was drawn using Figdraw.
Figure 3
Figure 3
Regulation of EGCG on tumor metabolic reprogramming. EGCG downregulates the expression or/and directly inhibits the activity of various key metabolic enzymes and molecular proteins required for glucose uptake, aerobic glycolysis, glutamine metabolism, fatty acid anabolism, and nucleotide synthesis pathways. The figure was drawn using Figdraw.

Similar articles

Cited by

References

    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) (2021) 134(7):783–91. doi: 10.1097/cm9.0000000000001474 - DOI - PMC - PubMed
    1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. . Cancer statistics for the year 2020: An overview. Int J Cancer (2021) 149:778–89. doi: 10.1002/ijc.33588 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Arneth B. Tumor microenvironment. Medicina (Kaunas) (2019) 56(1):15. doi: 10.3390/medicina56010015 - DOI - PMC - PubMed
    1. Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther (2021) 221:107753. doi: 10.1016/j.pharmthera.2020.107753 - DOI - PMC - PubMed

Publication types